Fasenra
Sanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polyps
Phil Taylor
AstraZeneca, Dupixent, Fasenra, fda, GlaxoSmithKline, inflammatory diseases, nasal polyps, Nucala, Regeneron, Sanofi
0 Comment
EU clears GSK’s asthma drug Nucala in patient-friendly format
Phil Taylor
AstraZeneca, Fasenra, GlaxoSmithKline, Nucala, respiratory, severe asthma, Teva
0 Comment
News/ News/ R&D/ Top stories
AstraZeneca’s respiratory biologic fails again in COPD
Linda Banks
AZ, COPD, Fasenra, MedImmune, respiratory biologic, respiratory disease
0 Comment
AstraZeneca (AZ) and MedImmune, have announced that the latest trial of Fasenra (benralizumab) in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) did not provide a statistically-significant reduction in exacerbations.